Clinical Insights: Key Data Presented at ASH 2024 in MDS

Author(s):

Courtney DiNardo, MD, MSCE,Rami Komrokji, MD

Panelists discuss how oral decitabine/cedazuridine demonstrated meaningful clinical activity in patients with TP53-mutated myelodysplastic syndromes (MDS), with a 31% complete response rate and 16.1-month median overall survival, representing an important treatment advance for this traditionally poor-prognosis molecular subgroup.

EP: 1.Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

EP: 2.MDS Treatment Strategies: From Risk Assessment to Transplantation

EP: 3.Introducing Hypomethylating Agents for Patients With MDS

EP: 4.ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS

EP: 5.Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS

Now Viewing

EP: 6.Clinical Insights: Key Data Presented at ASH 2024 in MDS

EP: 7.A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status

EP: 8.Future Horizons in the Treatment of Myelodysplastic Syndromes

Video content above is prompted by the following:

• Can you share any key takeaways or additional data updates surrounding MDS presented at ASH 2024?
• Oral decitabine/cedazuridine in MDS and TP53 mutations.

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!